Contact Us
+91 -9891818024
Glaucoma-Related Optic Atrophy — Evaluation in Mexico**
Glaucoma is a leading cause of optic atrophy worldwide, caused by progressive damage to the optic nerve, usually — though not always — linked to raised eye pressure. Unlike many other causes of optic atrophy, glaucoma has well-established treatments that can slow or halt further damage, even though nerve loss already present cannot be reversed.
10+
years Experience
years Experience
5000+
Patients treated
Patients treated
100+
Countries served
Countries served
NABH
Guided facility
Guided facility
Why Mexican Patients Consider This Option
Patients often travel for a specialist second opinion on pressure control, surgical options, or when local treatment hasn’t stabilized their eye pressure or visual field despite standard therapy.
Meet The Team
Our Eye Specialists
Dr. Pawan
Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience
Retinal disorders, diabetic retinopathy, and advanced retina procedures. Provides diagnostic evaluation and treatment planning for international patients.
Dr.Pallavee
Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience
Areas of Focus: Cataract surgery, corneal disorders, refractive procedures, and glaucoma management. Provides comprehensive eye care and surgical expertise for global patients.
Dr. Robin
Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
Areas of Focus: Cataract surgery, corneal disorders, refractive procedures, and glaucoma management. Provides comprehensive eye care and surgical expertise for global patients.
How Stem Cell Therapy May Help
Our team focuses on confirming current eye pressure control, reviewing visual field trends over time, and discussing whether medication adjustment, laser treatment, or surgical options (such as trabeculectomy or drainage devices) are appropriate for your specific case. The priority is always halting further loss — restoring already-lost vision from glaucoma is not currently possible with any treatment, including regenerative approaches.
Is This Treatment Right for You?
Suitability depends on the stage and cause of the condition. Before travelling, our team reviews:
01Eye pressure trends over recent visits
02Visual field test history (to check for progression)
03Current glaucoma medications and past procedures
04OCT of the optic nerve
What Your Visit Includes
- Remote pre-screening based on reports shared in advance
- In-person evaluation by our ophthalmology and regenerative medicine team
- Diagnostic work-up to confirm disease stage and suitability
- Stem cell therapy administered under medical supervision
- A written follow-up plan your doctor in mexic can continue monitoring
Travelling from Maxico — What to Expect
- Visa and appointment logistics vary; our coordinator confirms current requirements before booking
- Treatment estimates are provided in USD and Mexican Peso equivalents on request
- All consultations and reports are available in English and Spanish
Reviews
What Our Patients Say
Bunty Singh
Excellent customer service and straight away got some improvement as my eye points stop hurting when i press them so and still on the healing process. Very experienced doctor and lovely people. Happy with it.
Aneeket Kushwah
I came from overseas specifically for treatment. The staff not only assisted me with transport but also made the whole experience hassle-free. The medical service was of the highest standard and I was very secure in Delhi.
Frequently Asked Questions
Will this replace my glaucoma medication?
“No, you must continue your prescribed pressure-lowering treatment. Our evaluation addresses the optic nerve component only.”
Is this suitable for early-stage glaucoma?
” This option is generally explored by patients with more advanced, stable optic nerve damage. Your reports will help our team advise on suitability.”
Can Mexico patients currently travel to India for this treatment?
“At present, no — India’s visa suspension for Mexico nationals is still in effect. A remote report review lets you prepare in advance.
”
